1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Press Releases
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-08 am EDT
10714.00 GBX   -1.40%
08:57aTagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
AQ
07:18aASTRAZENECA : Gets a Buy rating from JP Morgan
MD
07:05aTAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société ASTRAZENECA PLC
08:57aTagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patie..
AQ
07:05aTAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer pati..
BU
06:55aASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
04:30aEnhertu approved in the US as the first HER2-directed therapy for patients with HER2-lo..
AQ
08/05ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directe..
BU
08/05ASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
08/05CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indicat..
BU
08/05Calquence tablet formulation approved in the US across current indications
AQ
08/04Playing the plan, Mawer's international equity portfolio, EP115
AQ
08/04ASTRAZENECA : Lynparza approved in the EU as adjuvant treatment for patients with germline..
PU
08/01ASTRAZENECA : Transparency Directive - Form 6-K
PU
08/01ASTRAZENECA : Transaction by Person Discharging Managerial Responsibilities - Form 6-K
PU
07/29Michel Demare to succeed Leif Johansson as Non-Executive Chair of the Board
AQ
07/29ASTRAZENECA : Michel Demaré to succeed Leif Johansson as Non-Executive Chair of the Board ..
PU
07/29ASTRAZENECA : Q2 Earnings Snapshot
AQ
07/29ASTRAZENECA : H1 2022 results presentation
PU
07/29ASTRAZENECA : H1 2022 results clinical trials appendix
PU
07/29ASTRAZENECA : H1 2022 results announcement
PU
07/29ASTRAZENECA : H1 2022 results
PU
07/26ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patient..
AQ
07/26AstraZeneca's Survivors Have Heart and the Philadelphia Phillies Partner to Raise Heart..
AQ
07/25ASTRAZENECA : Tezspire recommended for approval in the EU by CHMP for the treatment of sev..
PU
07/25ASTRAZENECA : Enhertu granted Priority Review in the US for patients with HER2-low metasta..
PU
07/25ASTRAZENECA : Ultomiris recommended for approval in the EU by CHMP for the treatment of ad..
PU
07/25Importance of Full Vaccination Against COVID-19
AQ
07/25ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patien..
BU
07/25Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma
AQ
07/25Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with g..
AQ
07/25Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast ..
AQ
07/22UNIVERSITY OF BRISTOL : Pfizer-BioNTech and AstraZeneca vaccines offer high protection aga..
AQ
07/19Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer tre..
AQ
07/19ENHERTU Approved in the EU for Patients with HER2 Positive Metastatic Breast Cancer Tre..
AQ
07/19ASTRAZENECA : Enhertu approved in the EU for patients with HER2-positive metastatic breast..
PU
07/19Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer tre..
AQ
07/18UNIVERSITY OF OXFORD : Oxford vaccine saved most lives in its first year of rollout
AQ
07/18UK donates 1 million more doses of Oxford-AstraZeneca vaccine to Bangladesh
AQ
07/12STUDY : Cancer drug candidate helps regenerate nerves after spinal injury
AQ
07/12AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic
AQ
07/06Astrazeneca inks $1.2bn deal with US biotech firm
AQ
07/05AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening ha..
AQ
07/05ASTRAZENECA : to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening hae..
PU
07/01AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination..
BU
07/01New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten ..
AQ
07/01Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN..
AQ
06/30IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Resp..
BU
06/30ASTRAZENECA : Imfinzi plus chemotherapy significantly improved pathologic complete respons..
PU
06/28AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as A..
AQ
06/28Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e..
AQ
06/28Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e..
AQ
06/27Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive meta..
AQ
06/23ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Pot..
BU
06/23ASTRAZENECA : ALXN1840 shows rapid and sustained improvement in copper mobilisation from t..
PU
06/22AstraZeneca and Merck - Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus A..
AQ
06/22PROpel Phase III trial positive results of LYNPARZA (olaparib) plus abiraterone in 1st-..
AQ
06/22Improved outcome for prostate cancer patients in Phase III PROpel trial
AQ
06/21PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st..
BU
06/21Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTR..
BU
06/10AstraZeneca demonstrates pipeline and portfolio strength across malignant and rare haem..
AQ
06/09Astrazeneca - Evusheld significantly prevented COVID-19 disease progression or death in..
AQ
06/08AstraZeneca's Evusheld significantly reduces risk of developing severe COVID-19
AQ
06/08Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase ..
AQ
06/06GHANA'S 'LIVING LAB' : Building Community and Ecological Resilience through the Atebubu an..
AQ
06/06Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in pat..
AQ
06/06GHANA'S ‘LIVING LAB' : Building Community and Ecological Resilience through the Ateb..
AQ
06/06Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic..
AQ
06/05ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or D..
BU
06/04Absolutely Bananas - Don't Believe Claims That Covid Vaccines Contain Monkeypox
AQ
06/04CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic..
BU
06/02AstraZeneca's Pascal Soriot awarded British knighthood for services to UK life sciences..
AQ
05/27First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
BU
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
AQ
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
AQ
05/24AstraZeneca COVID-19 vaccine approved in the EU as third dose booster against COVID-19
AQ
05/24Trial Scheduled For April 2024 In BMS Patent Case Against AstraZeneca Regarding Anti-PD..
AQ
05/23AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on ASTRAZENECA PLC